LEADING THE WAY TO A BRIGHTER TOMORROW
A Year of Innovation, Advancement and Progress for Rare Disease.

2021 ANNUAL REPORT
# Table of Contents

- **Message from Peter** 3
- **Leading the Way in**
  - Patient Services 4
  - Empowering Rare Nonprofits 6
  - Education 8
  - Research 10
  - Policy and Advocacy 12
  - Community Development 14
- **Our Partners** 16
- **Financials** 22
The impact of the National Organization for Rare Disorders (NORD) has never been greater.

This year, we provided over $40 million in financial support through NORD Patient Assistance Programs, which reached more than 9,400 individuals and families. Along with our 336 member organizations – a group of incredible nonprofit and patient advocacy organizations around the country – we have made big strides in innovation, advocacy, programs, and strategic leadership in the rare disease space. In 2021, we welcomed 25 new Corporate Council members, bringing our network of companies engaging with experts in the rare community to 128. Throughout another year of virtual events and engagement, NORD welcomed thousands of attendees to our webinars and conferences and allocated more than $312,000 in research funding to seed grant awardees.

Our work over the last 38 years has been made possible by partners and donors like you. NORD’s motto – “Alone we are rare. Together we are strong” – is about the collective voice. From top to bottom, we emphasize collaborative relationships with the patient community, donors, companies researching and developing treatments and therapies for rare disorders, and all those who participate in our mission to improve the lives of people living with rare diseases.

NORD began in 1983 as a collective of patients and caregivers advocating for the Orphan Drug Act. From that first day, through to today, NORD has led the way to eliminate the struggle of rare diseases once and for all. We can achieve this future together, through leadership, advocacy, research, and patient support.

NORD celebrates our past as we strive for a better future. We continue to add chapters to our rich history to make an impact for the 300 million people worldwide affected by rare disease. There are over 25 million Americans – 1 in 10 people – who are living with a rare disease today, but despite incredible advancements in research and technology over the last 40 years, more than 90% of the estimated 7,000 known rare diseases do not yet have an FDA-approved treatment.

With your support, NORD will continue to grow and impact lasting change, so that we can meet the needs of the national and global rare community for many years to come.

PETER L. SALTONSTALL
President and CEO
As an integral resource to the rare disease community, we exist to help people navigate the challenges of living with a rare disease. Our goal is to provide access to the services and support the community needs to obtain the best care and treatment, and to help patients live their best lives.

Since 1983, we have been working alongside our community to find and provide resources that can assist with the financial burden that so often accompanies a rare diagnosis. We offer information to help the rare disease community navigate healthcare decisions. We also provide travel and lodging support services to those who are participating in various clinical trials and studies.

Thanks to your participation and support, we’ve expanded our services to offer the most comprehensive portfolio of person-centric assistance programs available today. One great example is NORD’s respite caregiver program – the first-of-its-kind in the country for the rare community. Since the program’s introduction in 2019 – and with support requests greatly exacerbated by the pandemic – we have provided 682 respite grants to rare disorder caregivers.

LEADING THE WAY IN PATIENT SERVICES

$40,698,802
in support provided to families

$693,784
given for non-medical relief

65,592
financial support claims processed

9,419
individuals received financial assistance

741
people received non-medical financial relief

145
people received clinical trial travel and lodging services

12
new patient assistance programs launched

50
states supported (plus Washington DC, Puerto Rico and Guam)
OUR COMMITMENT TO CONTINUED PROGRESS

With your support, we will advance our work and continue to:

• Deliver exemplary customer service for patients.
• Stay dedicated to sustainability so that we are here for the rare community as long as they need us.
• Partner with patients, their families and patient support organizations to understand and meet community needs.
• Provide information and services that meet the needs, preferences, and style of those we serve.
• Foster a culture of respect – one that values the life and experience of each individual – so that the individual feels fulfilled in every interaction with us.

“NORD’s Rare Caregiver Respite program was an absolute lifeline for our family this past year. With the respite program, I was able to select a family friend who I trusted, who was already adequately trained to handle my daughter’s needs, and I could have her provide respite whenever I needed it. The reimbursement process was easy, and payment was received promptly.”

ANNA W.
Parent
Anyone affected by a rare disease can count on our 40-year history, vast industry connections, and the true strength that comes from having an organizational powerhouse in their corner. Through our growing network of professional patient organizations and partners, we engage and connect individuals, families and caregivers with the appropriate rare disease communities. We also help garner interest, attention and support for rare diseases from researchers, clinicians, industry stakeholders, regulators and legislators.

NORD’s roots are to advocate for equity and inclusion of rare diseases in healthcare, research and treatment development fields. Our important work leveling the playing field continues to today, including through initiatives such as our Diversity, Equity and Inclusion (DEI) three-part webinar and toolkit series.

The program is open to all nonprofits and helped rare disease leaders better understand DEI as a concept and ultimately reach and represent a more diverse swath of patients and caregivers. NORD continues to help rare disease nonprofit leaders improve their capacity, strengthen their governance, connect with researchers and government regulators, and navigate research and drug development.

Our work in 2021 resulted in growth across the rare disease community—or in some cases, established a baseline for growth.

- 336 member organizations
- 25 members of our Rare Cancer Coalition®
- 1,171 views of our three-part webinar series “DEI for Rare Disease Nonprofits”
- 1,000+ unique visitors worldwide viewed the RareLaunch® Forming a Foundation and Research Ready Workshops

In 2021, we created the Hispanohablantes Advisory Committee, which works to engage diverse populations within the greater rare disease community.

- 700 nonprofit leaders
- 3 RareLaunch startup organizations achieved 501(c)(3) milestones
- 114 free passes awarded for the virtual 2021 NORD Summit®
- 14 webinars conducted that reached more than 3,110 leaders and other stakeholders
RARELAUNCH® RESEARCH READY WORKSHOP

Within our RareLaunch® program, two of our three ongoing startup organizations received 501(c)(3) designation and the third filed for designation. We developed a Learning Management System (LMS) to make the process of starting a nonprofit turnkey for leaders, while also supporting them in becoming ready to advance research. We held half-day virtual workshops with multiple sessions in April 2021, allowing members to hear from rare leaders and experts on how to move forward in these spaces.

OUR COMMITMENT TO CONTINUED PROGRESS

With your support, we will continue to:

• Expand our Diversity, Equity and Inclusion work with nonprofit leaders.
• Further our mission to reach those in the rare community representing the 6,000+ diseases without a nonprofit home and help them advocate for themselves by developing a nonprofit.
• Develop content and learning modules within the LMS to continue to make starting and growing a rare disease nonprofit turnkey.
• Grow our membership of nonprofit organizations.

"NORD’s RareLaunch® Program enabled me to fulfill my previously unattainable goal of launching a foundation. As someone with a rare and orphaned disorder, I enrolled in NORD’s RareLaunch® webinar. Through the in-depth knowledge gained and the resources made available, I had the confidence to launch my own 501c(3) foundation. The ongoing support from the knowledgeable RareLaunch® team was invaluable in guiding me through every step of the process. Thank you RareLaunch®!"

JO-ANN D’ANGELO
Founder & Chair, Parry Romberg Foundation

EMPOWERING RARE NONPROFITS
At NORD, we use the power of education to attack the issues affecting real people’s lives from a variety of angles. This work includes innovative partnerships and programs to:

- **EMPOWER AND EDUCATE:** We provide education on rare diseases, how to advocate for one’s health, how to cope and find others with shared experiences, and how to navigate insurance and research opportunities.

- **INFORM AND ENGAGE:** We work with students who are entering healthcare studies or who are young advocates. These newcomers will likely encounter rare diseases in their careers and are a key audience to ensure patients are screened for rare diseases.

- **GUIDE AND SUPPORT:** We support healthcare professionals through continuing education and by providing resources to share with patients.

“It is truly hard to have a rare cancer and have financial hardship in time of the pandemic but assistance like what your foundation is giving to us patients [is] really life-changing and for me a miracle on its own. This is truly a gift/blessing!”

ANA
Patient
OUR COMMITMENT TO CONTINUED PROGRESS
As we advance our work, we will:

• Continue our work on Diversity, Equity and Inclusion issues that affect the rare disease community.
• Produce educational videos on genetic testing capabilities, limitations, experiences and access.

Hosted our third annual Living Rare, Living Stronger® NORD Patient and Family Forum – welcoming 389 attendees over the two-day program and made the content available post-event, reaching another 96 attendees.

Held the 2021 NORD Rare Disease and Orphan Products Breakthrough Summit® virtually for the second year. More than 940 people registered, representing 33 different countries.

Launched our first e-newsletter for healthcare professionals, called Caring for Rare Quarterly, which quickly grew into our second most viewed e-newsletter.

Significant growth in our Continuing Medical Education (CME) program. Completed 21 CME programs and partnered with 13 NORD member organizations to host 13,153 healthcare professional participants and 1,227 patients and caregivers.

Published 20 new reports in the NORD Rare Disease Database, which is often the first place patients, caregivers, leaders, researchers and media contacts go to learn about a rare disease. Published 19 new rare disease videos in the NORD Video Library to complement rare disease reports and explain rare diseases to visual and auditory learners.

Formed seven new Students for Rare chapters. Ended the year with 25 student chapters and 10 student clubs.
Patient groups are an important force in driving rare disease research forward. Our research and scientific activities provide the rare disease community with innovative tools and evidence to promote the engagement in impactful research and the fostering of medical advances. Over the past few years, we helped launch more than 40 rare disease patient registries and built systems that serve tens of thousands of patients, enabling them to advance groundbreaking scientific research.

As part of our work, we:

- **SUPPORT** and empower the research of our member organizations through IAMRARE® – our registry platform – enabling research through the awarding of grants and actively engaging in research projects to improve data utility and research opportunities.

- **ADMINISTER** seed grant funding for basic and translational research that enables scientists to explore investigational treatments and cures.

- **ADDRESS** the gap in available rare disease relevant clinical outcome assessments, which are necessary for clinical trials.

- **PARTNER** with the Clinical Data Interchange Standards Consortium (CDISC) to develop rare disease-specific data standards.

- **CREATE** a culture of data-sharing and collaboration through our partnership with Critical Path Institute on the FDA-funded Rare Disease Cures Accelerator – Data and Analytic Platform (RDCA-DAP®).

---

An important goal of NORD is to address the diagnostic odyssey, to address the lack of standardization of care-management and lack of coordinated multi-disciplinary care… So the overarching goal is to increase knowledge sharing across all rare diseases and across the country to really accelerate the progress in rare diseases with regards to diagnosis treatment and research.”

**OLAF BODAMER**
MD, PhD, Associate Chief of Genetics and Genomics at Boston Children’s Hospital
OUR COMMITMENT TO CONTINUED PROGRESS

With your engagement, we will advance our work with plans to:

- **EXPAND** features within the registry platform to further power robust, high-quality rare disease research, including the ability to launch registry surveys in French and Spanish, and expand our efforts help registry sponsors develop new registries.

- **CONTINUE EDUCATING** for individual patients, caregivers and patient groups to understand the research landscape, drug development process, and data literacy programs.

**IMPACT AT A GLANCE**

We helped 6 organizations launch their natural history studies on NORD’s IAMRARE® research collaboration platform:

- **The Aplastic Anemia and MDS International Foundation (AAMDSIF)**
  Paroxysmal Nocturnal Hemoglobinuria (PNH)

- **The Association for Creatine Deficiencies (ACD)**
  Cerebral Creatine Deficiency Syndromes (CCDS)

- **The Cure MLD and The Calliope Joy Foundation**
  Metachromatic Leukodystrophy (MLD)

- **The Cute Syndrome Foundation**
  SCN8A (also known as SCN8A Mutation, Cute Syndrome, SCN8A DEE and SCN8A Epilepsy)

- **The Gorlin Syndrome Alliance**
  Gorlin Syndrome

- **Tatton Brown Rahman Syndrome Community**
  Tatton-Brown Rahman Syndrome (TBRS, also known as DNMT3A Overgrowth Syndrome)

Reached a total of **14,875 individuals** across **29** different disease-specific registries through the IAMRARE® platform, who have collectively reported data for **143,253** surveys.

Thanks to donor generosity, we issued **$312,060** in research funding to seed grant awardees.

Our awareness activities for the RDCA-DAP reached **40,000** individuals with **4,000** unique views of webinars and our podcast.
LEADING THE WAY IN
POLICY AND ADVOCACY

For decades, we have pursued federal and state policies that have improved and continue to improve the lives of Americans impacted by rare diseases. NORD itself was founded by advocates who worked to pass the Orphan Drug Act (ODA), which has resulted in a dramatic increase in research and development of new treatments and cures for rare diseases. Supported by your participation, engagement and funding, our work includes:

- **BUILDING A MOVEMENT:** Through grassroots organizing across the country, we build community, encourage active participation and rally others to join in support of our mission.

- **FOREFRONT OF PUBLIC POLICY:** NORD works on the front lines of policy, government, and regulatory affairs to stand up for individuals with rare diseases and fight for life-changing policies.

- **STRONGER TOGETHER:** We build partnerships and join coalitions to raise awareness and advance our advocacy goals, demanding change from lawmakers that will ensure access to quality, affordable health care and new and better treatments.

- **DEVELOPING AND SHARING RESOURCES:** We connect individuals with local resources and empower them to make their voices heard.

"NORD’s Project RDAC (Rare Disease Advisory Council) resources and materials were critical in helping the Massachusetts RDAC bring our first meeting to order in September 2021. Since that first meeting, NORD has connected us with a network of leaders from other established RDACs, who have provided us with guidance and support as we have developed our council’s plan to make tangible improvements in the lives of people with rare diseases in Massachusetts."

**DYLAN TIERNEY**
MD MPH, MA RDAC Chair
OUR COMMITMENT TO CONTINUED PROGRESS
As we advance our work, we will:

• ADVOCATE in new states to increase the number of Rare Disease Advisory Councils (RDACs) and continue engagement with RDACs signed into law to ensure their effectiveness.

• GROW our reach with our advocacy network through new engagement initiatives and data-driven policy work.

STATE REPORT CARD*: Published the 6th edition of our annual State Report Card®, grading all 50 states based on how their policies impacted the lives of patients with rare disorders. We upgraded our website to include issue specific patient stories, as well as interactive maps for each state and policy area.

PROJECT RDAC: Developed several resources, including toolkits and model legislation, to assist with the creation of Rare Disease Advisory Councils (RDACs) at the state level.

21 states had signed legislation into law creating Rare Disease Advisory Councils by the end of 2021.

ADVOCATING FOR AFFORDABLE AND ACCESSIBLE HEALTH COVERAGE:
In 2021, we advocated to improve access and affordability of health insurance at both the state and federal level.

A NORD-led sign on letter with 86 patient advocacy organizations was sent to Congress to oppose changes to the Orphan Drug Tax Credit under consideration as part of the Build Back Better Act.

TELEHEALTH ADVANCEMENT: Continued to engage in telehealth legislation at the federal and state levels to permanently protect access that was afforded during the pandemic.

238 organizations added their signatures to a NORD letter to governors to protect access to telehealth services from out-of-state providers.
LEADING THE WAY IN

COMMUNITY DEVELOPMENT

An important aspect of NORD’s work is helping others understand what we do, the value of our programs and services, and, ultimately, the impact that we have. Through the tremendous generosity of our donors, we build partnerships, raise funds, and help others understand the depth of our commitment to serve the rare disease community. Likewise, we help donors understand what their support enables us to achieve and that we are good stewards of their financial support.

Thanks to our many financial partners and donors, we can make big strides to:

- **ELEVATE** the impact and value of our programmatic work.
- **DRIVE INNOVATION** and leadership in the rare disease sector.
- **EXPAND** and solidify our reach and collaboration with the community.
- **JOIN FORCES** with others through partnerships, fundraising, end-of-year campaigns and exhibiting at conferences.
- **NUTURE** collaborative relationships with donors (both individuals and family foundations), companies researching and developing treatments for rare disorders (including our Corporate Council Members), Foundation supporters, runners, community partners and all those who participate in and support our events.

Our belief is that the Center of Excellence program is the next big stride forward for rare disease treatment and patients—to improve health equity and create critical new connections to resources and specialists across our nation. NORD is committed to breaking down silos and building bridges so that people living with a rare disease can achieve their best health and well-being.”

**ED NEILAN**
Chief Scientific and Medical Officer, NORD
NEW INITIATIVE SPOTLIGHT: THE NORD RARE DISEASE CENTERS OF EXCELLENCE

Launched in November 2021, the NORD Rare Disease Centers of Excellence (CoE) Program brings together teams of clinical experts in a nationwide network of cutting-edge facilities, with the goal to provide standards of specialized care and disease management for people living with rare disease.

Patients will be able to access 31 designated centers nationwide, with each center offering access to the best possible coordinated multi-specialty clinical care and diagnostic opportunities for rare diseases.

The centers that form the NORD CoE network will work in partnership to share expertise, advance education, define standards and protocols, and shape the field of rare disease care, ultimately enabling rare disease patients to better navigate their diagnostic journey and find qualified medical homes for their complex medical conditions.

OUR COMMITMENT TO CONTINUED PROGRESS

Together with partners like you, we will:

- Continue looking for opportunities to diversify fundraising streams through multi-year funding support and philanthropic partnerships.
- Expand the impact of our rare disease work to positively touch more lives.
OUR PARTNERS
2021 BOARD OF DIRECTORS

KAY HOLCOMBE, CHAIR
Senior Advisor, Milken Institute Center for Public Health

FREDERICK (RICK) E. BARR, MD, MBA
Executive Vice-President and Chief Clinical & Academic Officer, Arkansas Children’s Hospital

RONALD J. BARTEK
President/Director/Co-founder Friedreich’s Ataxia Research Alliance (FARA)

SUSAN A. BERRY, MD
University of Minnesota

2021 MEDICAL & SCIENTIFIC ADVISORS

MARSHALL L. SUMMAR, MD (CHAIR)
Division Chief, Genetics and Metabolism
Margaret O’Malley Chair of Molecular Genetics
Children’s National Medical Center
Professor, Pediatrics, George Washington University School of Medicine and Health Sciences

MATTHIAS BAUMGARTNER, PROF DR MED
Associate Professor for Metabolic Diseases
University of Zurich
Head, Division of Metabolics
Children’s Hospital Zurich

HARRY (HAL) DIETZ, MD
Professor of Pediatrics, Associate Professor of Medicine, Assistant Professor of Neurological Surgery at Johns Hopkins University School of Medicine
Victor A. McKusick Professor of Genetics
Director, William S. Smilow Center for Marfan Syndrome Research

MARLENE HAFFNER, MD, MPH
President and CEO
Haffner Associates, LLC

STEVEN GROSSMAN, JD
President, HPS Group, LLC

SUSAN HEDSTROM
Executive Director, Foundation for Prader-Willi Research

DENNIS J. JACKMAN
Independent Board & Organizational Consultant

SHAFALI SPURLING JESTE, MD
Children’s Hospital Los Angeles
USC Keck School of Medicine

JAMES F. LECKMAN, MD
Nelson Harris Professor of Child Psychiatry
Psychiatry, Psychology and Pediatrics
Yale Child Study Center
Yale School of Medicine

JAMES E. LOCK, MD
Cardiologist-in-Chief
Boston Children’s Hospital
Alexander S. Nadas Professor of Pediatrics
Harvard Medical School

SUSAN WINTER, MD
Clinical Professor, Pediatrics, UCSF
Clinical Geneticist, Genetic Medicine and Metabolism, Valley Children’s Hospital

FREDERICK ASKARI, MD, PHD
Associate Professor, Hepatology
Division of Gastroenterology
Director, Wilson Disease Program
University of Michigan Health System

GREGORY M. ENNS, MB, CHB
Associate Professor of Pediatrics (Genetics)
Lucile Packard Children’s Hospital
Director, Biochemical Genetics Program, Mary L. Johnson Speciality Services
Associate Professor – Med Center Line, Pediatrics – Medical Genetics
Member, Child Health Research Institute
Stanford University School of Medicine

BRENDAN LEE, MD, PHD
Robert and Janice McNair Endowed Chair and Professor Molecular and Human Genetics
Baylor College of Medicine
Director, Center for Skeletal Medicine and Biology
Baylor College of Medicine
Director, Skeletal Dysplasia Clinic
Texas Children’s Hospital

MARY JEAN SAWEY, PHD
VP, Medical Director
Scientific Services
TRIO, an FCB Health Network Company

JIM PALMA
Executive Director, Target Cancer Foundation

PHILLIP L. PEARL, MD
Director, Epilepsy and Clinical Neurophysiology, Boston Children’s Hospital

MIKE PORATH
Founder and CEO, The Mighty

PETER L. SALTONSTALL
President and CEO, National Organization for Rare Disorders
**2021 Member Organizations**

A Cure For Ellie  
A Cure in Sight  
A Twist of Fate-ATS  
Achalasia Awareness Organization  
Acid Maltase Deficiency Association  
Acromegaly Community, Inc  
ADNP-Kids Research Foundation  
Adrenal Insufficiency United  
Adult Polyglucosan Body Disease Research Foundation  
Advocacy & Awareness for Immune Disorders Association  
Alagille Syndrome Alliance  
All Things Kabuki  
Alpha-1 Foundation  
Alport Syndrome Foundation  
Alternating Hemiplegia of Childhood Foundation  
American Behcet’s Disease Association  
American Multiple Endocrine Neoplasia Support  
American Partnership for Eosinophilic Disorders  
American Porphyria Foundation  
Amniotic Fluid Embolism Foundation  
Amyloidosis Research Consortium, Inc  
Amyloidosis Support Groups, Inc  
Angioma Alliance  
Aplastic Anemia & MDS  
Appendix Cancer / Pseudomyxoma Peritonei Research Foundation (ACPMP)  
Association For Creatine Deficiencies  
Association for Frontotemporal Degeneration  
Association for Glycogen Storage Disease  
Association of Gastrointestinal Motility Disorders, Inc  
ASXL Rare Research Endowment Foundation  
Autoimmune Encephalitis Alliance  
Autoimmune Hepatitis Association  
Autoimmune Polyglucosan Syndrome Type 1 Foundation  
Avery’s Hope  
AXYS  
Batten Disease Support & Research Association  
BCM Families Foundation  
BORN A HERO, Pfeiffer’s Health and Social Issues Awareness  
Bridge the Gap-SYNGAP Education & Research Foundation  
CACNA1A Foundation  
Calliope Joy Foundation  
Canadian Organization For Rare Disorders  
Cardio-Facio-Cutaneous International  
Castleman Disease Collaborative Network  
Cauda Equina Foundation  
CHAMP1 Research Foundation  
Charcot-Marie-Tooth Association  
Child And Youth Care  
Child Neurology Foundation  
Children’s Craniofacial Association  
Children’s PKU Network  
Children’s Tumor Foundation, Inc  
Cholangiocarcinoma Foundation  
Choroideremia Research Foundation  
Chromosome 18 Registry & Research Society  
Chromosome Disorder Outreach, Inc  
Cicatricial Alopecia Research Foundation  
Cloves Syndrome Community  
Clusterbusters, Inc  
Cmt Research Foundation  
CMTC-OVM Netherlands  
Coalition to Cure Calpain 3  
Congenital Central Hypoventilation Syndrome Family Network (CCHS Family Network)  
Congenital Hyperinsulinism International Consortium of Multiple Sclerosis Centers  
COPA Syndrome Foundation  
CRMO Foundation  
CSNK2A1 Foundation  
Cure Cmd  
CURE HHT Foundation  
Cure SMA  
Cure VCP Disease, Inc  
CureCADASIL/CADASIL Association, Inc  
CureDuchenne  
CureGRIN Foundation  
CurePSP  
Curing Retinal Blindness Foundation  
Cushing’s Support & Research Foundation, Inc  
Cutaneous Lymphoma Foundation  
Cystic Fibrosis Foundation  
Cystic Fibrosis Research Inc. (cfri)  
Cystinosis Research Network, Inc  
Danny’s Dose Alliance  
The Defeat Ms Alliance  
Desmoid Tumor Research Foundation  
DESSH DeSanto-Shinawi Syndrome Corp  
DHPS Foundation  
Dreamsickle Kids Foundation  
Dup15q Alliance  
Dyrk1a Syndrome Us  
Erdeihem-Chester Disease Global Alliance  
Erythromelalgia Association  
Eurordis  
Familial Dysautonomia Foundation  
Fanconi Anemia Research Fund  
Fat Disorders Resource Society, Inc  
Fibrolamellar Cancer Foundation  
Fibromuscular Dysplasia Society Of America  
Foundation Fighting Blindness  
Foundation For Angelman Syndrome Therapeutics  
Foundation For Ichthyosis and Related Skin Types  
Foundation For Prader-willi Research  
Foundation For Sarcoïdosis Research  
Foundation for USP-7 Related Diseases  
Foundation to Fight H-abc  
FPIES Foundation  
Friedreich’s Ataxia Research Alliance (FARA)  
Galactosemia Foundation  
Gaucher Community Alliance  
GBS|CIDP Foundation International  
Genetic Alliance  
Genetic Alliance Australia  
Global Dare Foundation  
Glut1 Deficiency Foundation  
Gorlin Syndrome Alliance  
Gould Syndrome Foundation  
Grin2b Foundation  
Gut Check Foundation  
Guthy Jackson Charitable Foundation  
Hemophilia Federation Of America  
Hepatitis Delta Connect - Hepatitis B Foundation  
Hermansky-Pudlak Syndrome Network, Inc  
Hereditary Neuropathy Foundation  
HCU Network America  
HCU Network Australia  
Helping Hands for GAND, Inc.  
Hereditary Hypothyroidism International  
Hermansky-Pudlak Syndrome Network, Inc  
Hepatitis Delta Connect - Hepatitis B Foundation  
Hermansky-Pudlak Syndrome Network, Inc  
Hermansky-Pudlak Syndrome Network, Inc  
Hermansky-Pudlak Syndrome Network, Inc  
Hermansky-Pudlak Syndrome Network, Inc  
Hermansky-Pudlak Syndrome Network, Inc  
Hermansky-Pudlak Syndrome Network, Inc  
Hermansky-Pudlak Syndrome Network, Inc  
Hermansky-Pudlak Syndrome Network, Inc  
Hermansky-Pudlak Syndrome Network, Inc  
Hermansky-Pudlak Syndrome Network, Inc  
Hermansky-Pudlak Syndrome Network, Inc  
Hermansky-Pudlak Syndrome Network, Inc
Histiocytosis Association, Inc
Hope For Hypothalamic Hamartomas
HSANIE Society
Hydrocephalus Association
Illness Challenge Foundation
Immune Deficiency Foundation
Indian Organization For Rare Diseases
International Autoimmune Encephalitis Society
International FOP Association, Inc
International Foundation for CDKL5 Research
International FPIES Association
International Neuroendocrine Cancer Alliance
International Pemphigus & Pemphigoid Foundation
International Rett Syndrome Foundation (dba. Rettsyndrome.org)
International Sacral Agenesis/Caudal Regression Association
International Wagr Syndrome Association
International Waldenström’s Macroglobulinemia Foundation
ISMRD
Jack McGovern Coats Disease Foundation
Joshua Frase Foundation for Congenital Myopathy Research
Julia’s Wings Foundation, Inc
KAT6A Foundation
Kennedy’s Disease Association, Inc
Kif1a.org
Kindness for Kimberlee
Klippe Trenaunay Support Group
Krabbeconnect
LAL Solace, Inc
Li-Fraumeni Syndrome Association
Liv4TheCure
Lowe Syndrome Association, Inc
Lung Transplant Foundation
Lymphangiomatosis & Gorham’s Disease Alliance, Inc
Malan Syndrome Foundation
Marfan Foundation
Martin Mueller IV Achalasia Awareness Foundation, Inc
M-CM Network
Mebo Research, Inc
Melanoma Research Foundation
Melorheostosis Association
Mila’s Miracle Foundation
Mitoaction
MLD Foundation
Moebius Syndrome Foundation
Mowat-Wilson Syndrome Foundation
MPN Research Foundation
MSUD Family Support Group
Mucolipidosis Type IV Foundation, Inc
Multiple System Atrophy Coalition, Inc
Muscular Dystrophy Association
Myasthenia Gravis Foundation of America, Inc
Myhre Syndrome Foundation
Myocarditis Foundation
Myotonic Dystrophy Foundation
National Adrenal Diseases Foundation
National Ataxia Foundation
National CMV (Cytomegalovirus) Foundation
National Eosinophilia Myalgia Syndrome Network
National Foundation for Ectodermal Dysplasias
National Health Council
National Hemophilia Foundation
National Leiomyosarcoma Foundation
National Median Arcuate Ligament Syndrome Foundation
National MPS Society
National Niemann-Pick Disease Foundation
National Organization for Albinism & Hypopigmentation
National Pku Alliance
National PKU News
National Tay-Sachs & Allied Diseases Association
National Urea Cycle Disorders Foundation
NBIA Disorders Association
Necrotizing Enterocolitis Society
NephCure Kidney International
Neuroendocrine Tumor Research Foundation
Neurofibromatosis Network
Neurofibromatosis Northeast
Neuromuscular Disease Foundation
Ocular Melanoma Foundation
OMSLife Foundation
Organic Acidemia Association
Organization for Rare Diseases India
Osteogenesis Imperfecta Foundation
Our Odyssey
PAP Foundation, Inc.
Parent Project Muscular Dystrophy
Parent to Parent New Zealand, Inc
Patient AirLift Services
Perthes Kids Foundation
Phelan-mcdermid Syndrome Foundation
Pheno Para Alliance
Pituitary Network Association
PKD Foundation
Platelet Disorder Support Association
Prader-Willi Syndrome Association (USA)
Primary Ciliary Dyskinesia Foundation
PRISMS (Parents & Researchers Interested in Smith-Magenis Syndrome)
Spastic Paraplegia Foundation
Spina Bifida Association
Spinal CSF Leak Foundation
SSADH Association
Stevens Johnson Syndrome Foundation
STXBP1 Foundation
Sudden Unexplained Death in Childhood Foundation
Superficial Siderosis Research Alliance, Inc.
Taiwan Foundation for Rare Disorders
Talia Duff Foundation, Inc.
TANGO2 Research Foundation
TargetCancer Foundation
Tarlov Cyst Disease Foundation
Tatton Brown Rahman Syndrome Community
Team Telomere
Tess Research Foundation
The ALS Association
The Avalon Foundation
The Bonnell Foundation: living with cystic fibrosis
The Cute Syndrome Foundation
The E.WE Foundation
The EHE Foundation
The Ehlers-Danlos Society
The FD/MAS Alliance
The Global Foundation For Peroxisomal Disorders
The Hyper IgM Foundation
The Hypersomnia Foundation
The Jansen’s Foundation
The Lam Foundation
The Life Raft Group
The Mast Cell Disease Society
The Myositis Association
The Oley Foundation
The Progeria Research Foundation, Inc.
The Snow Foundation
The Yellow Brick Road Project
Transplant Unwrapped
TSC Alliance
Turner Syndrome Society of the United States
Tyrosinemia Society, Inc.
United Leukodystrophy Foundation
United Mitochondrial Disease Foundation
United Msd Foundation
Usher Syndrome Coalition
Vasculitis Foundation
Vestibular Disorders Association
VHL Alliance
Wilhelm Foundation
Williams Syndrome Association
Worldwide Syringomyelia & Chiari Task Force, Inc
Xia-Gibbs Society, Inc
XLH Network, Inc
# 2021 Corporate Council Members

## Pre-Clinical Research

- Acer Therapeutics
- Cabaletta Bio
- Cellectar
- gMendel
- Jaguar Gene Therapies, LLC
- Neurogene
- Orna Therapeutics, Inc
- Praxis Precision Medicines
- Shape Therapeutics
- Soligenix, Inc.
- Stride Bio
- Taysha Gene Therapies
- Vigil Neuroscience, Inc.

## Clinical Development

- Acer Therapeutics, Inc.
- Aeglea BioTherapeutics
- Apellis Pharmaceuticals
- Applied Therapeutics
- argenx
- Ascendis Pharma
- Asklepion Pharmaceuticals, LLC
- Atara Biotherapeutics
- Avadel Pharmaceuticals
- AVROBIO
- bluebirdbio
- Blueprint Medicines
- BridgeBio
- Camurus
- ChemoCentryx
- CRISPR Therapeutics
- Cytokinetics, Inc.
- Dicerna
- Editas Medicine
- Enzyvant
- Exicure
- Helimith Co, Ltd.
- Insmed Incorporated
- Kezar Life Sciences, Inc.
- Kiniksa Pharmaceuticals
- Larimar Therapeutics
- LEO Pharma
- Lysogene
- MeiraGTx
- Mereo BioPharma
- Moderna Therapeutics
- Neurocrine Biosciences
- Orchard Therapeutics Ltd.
- Orphazyme
- Ovid Therapeutics
- Passage Bio
- PharmaEssentia
- Prevail Therapeutics
- Rallybio
- REGENXBIO
- Rocket Pharmaceuticals, Inc
- Sangamo Therapeutics
- Saniona
- Santen
- Savara
- Sigilon Therapeutics
- Synlogic Therapeutics
- UniQure
- Wave Life Sciences
- X4 Pharmaceuticals
- Zealand Pharma

## Approved Product

- AbbVie Pharmaceuticals
- Acadia Pharmaceuticals
- Acceleron Pharma
- Agios Pharmaceuticals
- Alexion, AstraZeneca Rare Diseases
- Alnylam Pharmaceuticals
- Amgen
- Amicus Therapeutics, Inc.
- Astellas
- AstraZeneca
- BioCryst
- Biogen
- BioMarin Pharmaceuticals, Inc.
- Boehringer-Ingelheim Pharmaceuticals, Inc.
- Bristol –Myers Squibb
- Catalyst Pharmaceuticals
- Chiesi Global Rare Diseases
- CSL Behring
- Daiichi Sankyo
- Deciphera
- Dompé
- Eiger BioPharmaceuticals
- Foundation Medicine
- Genentech, Inc.
- GlaxoSmithKline PLC
- Global Blood Therapeutics, Inc.
- Greenwich Biosciences, Inc
- Harmony Biosciences, LLC
- Horizon Therapeutics
- Incyte Corporation
- Ionis Pharmaceuticals
- Ipsen Biopharmaceuticals
- Janssen Pharmaceuticals
- Mallinckrodt Pharmaceuticals
- Neurocrine Continental, Inc.
- Novartis
- Otsuka America, Inc.
- Pfizer, Inc.
- PTC Therapeutics
- Recordati Rare Diseases, Inc.
- Regeneron Pharmaceuticals, Inc.
- Rigel Pharmaceuticals
- Sanofi Genzyme
- Sarepta Therapeutics
- Sobi
- Spark Therapeutics
- Stemline Therapeutics
- Strongbridge Biopharma
- Takeda
- Traverere Therapeutics, Inc.
- UCB Pharma
- Ultragenyx
- Vanda Pharmaceuticals Inc.
- Vertex Pharmaceuticals Worldwide
- Zogenix, Inc.

## Business Member

- Biotechnology Industry Organization (BIO)
- Eversana
- HPS Group LLC
- ICON
- Illumina
- Medidata
- Optum Frontier Therapies
- Parexel International
- PhRMA
- Syneos Health
FINANCIALS
2021 REVENUE

- $46,999,589 Patient Service Contributions and Fees
- $2,145,585 Organization and Corporate Membership Dues
- $1,888,596 Special Events
- $8,720,385 Other Contributions, Grants and Service Revenue

$59,754,155 Total Unrestricted & Released Donor-Restricted Revenue

2021 EXPENSES

- Program Services $52,898,299
- General and Administrative $3,138,306
- Development and Communications $1,694,897

Total Expenses $57,731,502
# Financials

## Statements of Financial Position December 31, 2021 and 2020

### Assets

<table>
<thead>
<tr>
<th>Category</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$13,488,659</td>
<td>$23,512,112</td>
</tr>
<tr>
<td>Accounts, grants and contributions receivable, net of allowance for doubtful accounts of $25,000 and $200,000 at December 31, 2021 and 2020, respectively</td>
<td>$1,240,510</td>
<td>$1,358,053</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>$351,001</td>
<td>$368,116</td>
</tr>
<tr>
<td>Investments</td>
<td>$20,808,366</td>
<td>$25,613,110</td>
</tr>
<tr>
<td><strong>Total Current Assets</strong></td>
<td><strong>$35,888,536</strong></td>
<td><strong>$50,851,391</strong></td>
</tr>
<tr>
<td>Restricted Cash</td>
<td>--</td>
<td>$200,000</td>
</tr>
<tr>
<td>Investments - Deferred Compensation</td>
<td>$147,299</td>
<td>$108,394</td>
</tr>
<tr>
<td>Investments - Endowment</td>
<td>$244,364</td>
<td>--</td>
</tr>
<tr>
<td>Deferred Hosting Arrangement Costs</td>
<td>$74,147</td>
<td>$109,919</td>
</tr>
<tr>
<td>Property, equipment and software, net</td>
<td>$1,248,813</td>
<td>$1,316,605</td>
</tr>
<tr>
<td>Software Under Development</td>
<td>$272,087</td>
<td>$188,231</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$37,875,246</strong></td>
<td><strong>$52,774,540</strong></td>
</tr>
</tbody>
</table>

### Liabilities and Net Assets

#### Current Liabilities:

<table>
<thead>
<tr>
<th>Category</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current portion of long-term debt</td>
<td>$74,640</td>
<td>$70,844</td>
</tr>
<tr>
<td>Accounts payable</td>
<td>$513,301</td>
<td>$587,335</td>
</tr>
<tr>
<td>Accrued expenses</td>
<td>$922,684</td>
<td>$662,999</td>
</tr>
<tr>
<td>Current portion of research grants payable</td>
<td>$548,527</td>
<td>$1,098,220</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>$242,900</td>
<td>$248,181</td>
</tr>
<tr>
<td><strong>Total Current Liabilities</strong></td>
<td><strong>$2,302,052</strong></td>
<td><strong>$2,667,579</strong></td>
</tr>
<tr>
<td>Deferred Compensation</td>
<td>$147,299</td>
<td>$108,394</td>
</tr>
<tr>
<td>Research Grants Payable, net of current portion</td>
<td>$393,758</td>
<td>$265,000</td>
</tr>
<tr>
<td>Long-Term Debt, net of current portion</td>
<td>$90,440</td>
<td>$165,915</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>$2,933,549</strong></td>
<td><strong>$3,206,888</strong></td>
</tr>
</tbody>
</table>

#### Net Assets:

<table>
<thead>
<tr>
<th>Category</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating</td>
<td>$7,789,738</td>
<td>$5,877,691</td>
</tr>
<tr>
<td>Property, equipment and software</td>
<td>$1,355,820</td>
<td>$1,268,077</td>
</tr>
<tr>
<td>Board designated endowment</td>
<td>$22,863</td>
<td>--</td>
</tr>
<tr>
<td><strong>Total Without Donor Restrictions</strong></td>
<td><strong>$9,168,421</strong></td>
<td><strong>$7,145,768</strong></td>
</tr>
</tbody>
</table>

**With donor restrictions:**

<table>
<thead>
<tr>
<th>Category</th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Net Assets</td>
<td>$34,941,697</td>
<td>$49,567,652</td>
</tr>
<tr>
<td>Total Liabilities and Net Assets</td>
<td>$37,875,246</td>
<td>$52,774,540</td>
</tr>
</tbody>
</table>
### STATEMENTS OF ACTIVITIES WITHOUT DONOR RESTRICTIONS FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020

#### Changes in Net Assets Without Donor Restrictions

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient services:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program fees</td>
<td>$182,934</td>
<td>$345,353</td>
</tr>
<tr>
<td>Net assets released from purpose restrictions</td>
<td>43,844,645</td>
<td>39,755,627</td>
</tr>
<tr>
<td>Patient assistance and reimbursement expense</td>
<td>(44,198,311)</td>
<td>(40,100,980)</td>
</tr>
<tr>
<td>Patient services, net</td>
<td>(170,732)</td>
<td>--</td>
</tr>
<tr>
<td><strong>Research grants:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net assets released from purpose restrictions</td>
<td>--</td>
<td>631,258</td>
</tr>
<tr>
<td>Research grant expense</td>
<td>--</td>
<td>(631,258)</td>
</tr>
<tr>
<td>Research grants, net</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td><strong>Other revenue and support:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grants, contributions and bequests</td>
<td>$3,363,185</td>
<td>$4,122,303</td>
</tr>
<tr>
<td>Special events revenue</td>
<td>1,888,596</td>
<td>1,900,601</td>
</tr>
<tr>
<td>Registry, web subscriptions and other related fees</td>
<td>1,000,570</td>
<td>395,674</td>
</tr>
<tr>
<td>Investment return, net</td>
<td>64,185</td>
<td>273,125</td>
</tr>
<tr>
<td>Drug, travel and lodging program administrative fees</td>
<td>44,877</td>
<td>67,425</td>
</tr>
<tr>
<td>Investment return - endowment, net</td>
<td>22,863</td>
<td>--</td>
</tr>
<tr>
<td>Net assets released from purpose restrictions - contributions</td>
<td>4,224,705</td>
<td>1,755,460</td>
</tr>
<tr>
<td>Net assets released from purpose restrictions - patient service administrative fees</td>
<td>2,972,010</td>
<td>3,756,095</td>
</tr>
<tr>
<td>Net assets released from time restrictions - membership dues</td>
<td>2,145,585</td>
<td>1,783,062</td>
</tr>
<tr>
<td>Net assets released from purpose restrictions - research grant administrative fees</td>
<td>--</td>
<td>52,000</td>
</tr>
<tr>
<td><strong>Total Other Revenue and Support</strong></td>
<td>$15,726,576</td>
<td>$14,105,745</td>
</tr>
<tr>
<td><strong>Other operating expenses:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Personnel and related</td>
<td>$10,006,667</td>
<td>$8,470,391</td>
</tr>
<tr>
<td>Professional fees</td>
<td>1,180,693</td>
<td>1,156,404</td>
</tr>
<tr>
<td>Occupancy</td>
<td>497,517</td>
<td>521,385</td>
</tr>
<tr>
<td>Data systems and equipment</td>
<td>487,430</td>
<td>456,801</td>
</tr>
<tr>
<td>Other</td>
<td>467,025</td>
<td>507,830</td>
</tr>
<tr>
<td>Depreciation</td>
<td>457,604</td>
<td>486,500</td>
</tr>
<tr>
<td>Conferences, meetings and travel</td>
<td>436,255</td>
<td>401,986</td>
</tr>
<tr>
<td><strong>Total Other Operating Expenses</strong></td>
<td>$13,533,191</td>
<td>$12,001,297</td>
</tr>
<tr>
<td><strong>Changes in Net Assets Without Donor Restrictions</strong></td>
<td>$ 2,022,653</td>
<td>$2,104,448</td>
</tr>
</tbody>
</table>